LENALIDOMIDE

Brand name:

• Lenalide®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Multiple myeloma (MM) Myelodysplastic syndromes (MDS) Mantle cell lymphoma (MCL)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (Category 4)

Comment:

--

Submission sponsor:

Juno Pharmaceuticals Pty Ltd

Other PBAC consideration:

--

Submission received for:

November 2023 PBAC meeting

Opportunity for consumer comment:

Open 26/07/2023 and close 20/09/2023 (see PBS Website)

PBAC meeting:

Held on 01/11/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

11/12/2023

Lodgement of required documentation:

22/01/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 21/06/2024

Status:

Finalised

Government processes:

Commenced on 20/08/2024

Medicine listed on the PBS:

01/10/2024 (see PBS schedule)

---